Yes-associated protein (YAP) is a downstream effector of the Hippo signaling pathway, which controls organ expansion and tissue development. We have recently defined the tumorigenic potential and clinical significance of the YAP1 oncogene in human hepatocellular carcinoma (HCC). The present study aims to define the tumorigenic properties of YAP in HCC and elucidate the related downstream signaling mechanism. In a gain-of-function study, we demonstrated that ectopic increased expression of YAP in the immortalized non-tumorigenic hepatocyte cell line MIHA confers tumorigenic and metastatic potentials, as evidenced by (1) enhanced aptitudes in cell viability, anchorage-independent growth, migration and invasion; (2) tumor formation in a xenograft mouse model; and (3) induction of HCC biomarker a-fetoprotein and activation of mitogen-activated protein kinase. Furthermore, we have identified AXL, a receptor tyrosine kinase, as a key downstream target that drives YAP-dependent oncogenic functions. RNAi-mediated knockdown of AXL expression decreased the ability of YAP-expressing MIHA cells and of the primary HCC cell line to proliferate and invade. These results indicate that AXL is a mediator of YAP-dependent oncogenic activities and implicates it as a potential therapeutic target for HCC.
Introduction
The Hippo signaling pathway, which was recently discovered in Drosophila, has an important role in organ size control during embryonic development and also represents a novel tumor suppressor pathway (Liu et al., 2010; Oh and Irvine, 2010) . Through genetic screening, the Hippo signaling components have been identified as a group of kinase molecules, including Merlin (Mer), Expanded (Ex), Hippo (Hpo), Salvador (Sav), Mob as tumor suppressor (Mats) and Warts (Wts). Essentially, the downstream effect of the Hippo signaling cascade is to phosphorylate and inactivate the Yorkie (Yki) effector molecule through cytoplasmic sequestration and proteolytic degradation (Edgar, 2006; Zeng and Hong, 2008; Zhao et al., 2008a Zhao et al., , 2010 . Dysregulation of Hippo signaling results in Yki protein dephosphorylation and nuclear accumulation, wherein, together with TEA domain (TEAD)/transcription enhancer factor family of transcription factors (for example, Scalloped), Yki could transactivate multiple gene targets such as cyclin E, diap1 and bantam microRNA (Thompson and Cohen, 2006; Bandura and Edgar, 2008; Wu et al., 2008) . Overexpression of the Yki/Scalloped target genes partly explains the cellular proliferation and inhibition of apoptosis, and malfunction of the upstream Hippo signaling kinases has been shown to cause tissue overgrowth or organ enlargement (Huang et al., 2005; Buttitta and Edgar, 2007; Pan, 2007; Yin and Pan, 2007) .
Yes-associated protein (YAP, YAP1 or YAP2) and its paralog TAZ have been identified as the Yki orthologs in humans, with similar regulatory mechanisms (Zhao et al., 2007; Hao et al., 2008; Lei et al., 2008) . Both YAP1 and TAZ are transcriptional co-activators of TEADs (Zhao et al., 2008a; Chan et al., 2009) . Using integrative oncogenomic and proteomic approaches, we have begun to discover novel tumor suppressors and oncogenes in hepatocellular carcinoma (HCC) carcinogenesis (Zender et al., 2006 , and recently identified YAP1 as a bona fide oncogene in mouse liver carcinoma (Zender et al., 2006) . Furthermore, YAP transgenic mice demonstrated a remarkable increase in liver size and eventually developed liver tumors (Camargo et al., 2007; Dong et al., 2007) . Overexpression of YAP1 in the normal breast epithelial cell line MCF10A induced epithelial-to-mesenchymal transition, resistance to apoptosis and enhanced anchorage-independent growth capability (Overholtzer et al., 2006) . Moreover, YAP activation might override cell-cell contact inhibition and promote cellular growth (Zhao et al., 2007) . In clinical specimens, overexpression and nuclear accumulation of YAP have been reported in prostate, colon, breast, non-small-cell lung cancer, as well as in ovarian and liver cancers (Zhao et al., 2007; Steinhardt et al., 2008) , and our clinical study in a cohort of 177 HCC patients further demonstrated that YAP is an independent prognostic marker associated with poor disease-free survival and overall survival in HCC (Xu et al., 2009) .
Despite its clinical importance, the molecular mechanisms of YAP or TAZ as oncogenic drivers in human cancers remain largely unknown. Here, we used a gainof-function study in the immortalized non-tumorigenic hepatocyte cell line MIHA and a loss-of-function study in the primary HCC cell line PLC/PRF/5 to elucidate the role of AXL receptor tyrosine kinase (AXL, a putative target of YAP (Zhao et al., 2008b) ) as a critical mediator of YAP-dependent oncogenic functions in HCC.
Results

Oncogenic transformation of the non-tumorigenic hepatocyte line MIHA by YAP1
The human YAP1 gene (NM_006106.3) was stably transfected into a human hepatocyte cell line MIHA and two independent clones (MIHA-YAP1a and MIHAYAP1b) were subsequently established for gain-offunction studies (see Supplementary Figure 1a) . First, we investigated the cell viability and proliferation of each MIHA-YAP clone by MTT assay (Figure 1a ; left panel); both MIHA-YAP1 clones exhibited faster growth rates compared with the empty vector control (MIHA-Vec) when grown in complete culture medium. In the absence of serum, however, MIHA and MIHAVec cells were unable to grow. Strikingly, the YAPexpressing MIHA cells were able to survive and proliferate ( Figure 1a ; center panel), suggesting that the YAP oncoprotein may rescue the non-tumorigenic hepatocyte line MIHA from growth arrest or provide survival/growth signals under serum-starved conditions. By contrast, when endogenous YAP expression in the tumorigenic primary HCC cell line (PLC/PRF/5) was suppressed by small interfering RNA interference (see Supplementary Figure 1b) , the growth rate of PLCsiYAP1a and PLC-siYAP1b cells was significantly impaired (Figure 1a ; right panel).
Clinical correlation analysis has revealed strong association of YAP expression level with serum a-fetoprotein (AFP) level and tumor recurrence in HCC (Xu et al., 2009) . Therefore, we next evaluated whether YAP-transformed MIHA cells would express the AFP biomarker for HCC. The clinical cutoff value for HCC diagnosis is 400 ng/ml; the AFP levels in the culture supernatants of MIHA-YAP1 clones ranged from 2000 to 4500 ng/ml at 5 days, but AFP was undetectable in the parental MIHA and vector controls (Figure 1b) . When grown on soft agar, both MIHA-YAP1 clones gave rise to anchorage-independent colonies (Figure 1c ), suggesting that YAP may suppress anoikis and override the contact inhibition, providing survival and growth signals.
To determine the metastatic potential of the YAP1 oncogene, we investigated the cell motility and invasion abilities of the MIHA-YAP1 clones using a wound healing assay (Figure 2a ) and a matrigel chamber assay (Figure 2b ), respectively. When compared with the MIHA-Vec control, faster wound closure was observed in MIHA-YAP1 clones at 48 h, and more cell penetration in Matrigel at 72 h.
Tumorigenic potential of YAP1-transfected MIHA cells in vivo MIHA is a non-tumorigenic hepatocyte cell line that is unable to form tumors in a subcutaneous xenograft nude mouse model. After YAP1 transformation, both MIHA-YAP1a and MIHA-YAP1b clones could form visible tumors in vivo, B4 weeks after inoculation ( Figure 3a ). Histological examination of the tumors revealed prominent intratumoral microvessels, AFP production and strong positive Ki-67 signals in tumor nuclei correlating with increased expression of YAP proteins (Figure 3b ).
YAP upregulates AXL receptor kinase expression in MIHA cells AXL receptor kinase is a putative target of YAP (Zhao et al., 2008b) , and activation of AXL can lead to activation of phosphoinositide 3-kinase/Akt and ERK1/ 2 mitogen-activated protein (MAP) kinase pathways (Hafizi and Dahlback, 2006) . Interestingly, we also found that AXL expression was upregulated in the YAP1-MIHA xenograft explants resected from the nude mice ( Figure 3b ). We then tested 10 pairs of clinical HCC samples by immunohistochemistry. Those YAP1-positive HCCs were also found to coexpress the AXL protein in the tumors, but not in the adjacent tissues (Supplementary Figure 2a) . To further investigate whether AXL is under the control of YAP in HCC, we screened the AXL promoter region and identified four putative TEAD-binding sites (TB) located within 1200 bp upstream of the transcriptional start site of AXL. As shown by the chromatin immunoprecipitation (ChIP) assay in MIHA-YAP1b lysates (Figure 4a ), immunoprecipitation by anti-YAP antibody, but not by the IgG control, gave a positive signal on PCR amplification of the AXL promoter spanning the TB1-TB2 (AXL-1) and TB3-TB4 (AXL-2) sites. Likewise, binding of YAP protein to the AXL promoter (both TB1-TB2 and TB3-TB4 sites) was also detected in primary HCC cell PLC/PRF/5 (PLC-control siRNA (siCon)), but not in PLC-siYAP1c and PLC-siYAP1d cells, for which the YAP expression was silenced by RNAi knockdown (Figure 4b ).
To further demonstrate YAP cotranscriptional activity on AXL expression, we conducted luciferase reporter (Figure 4c ). The pGL3-basic Luc vector subcloned with the AXL (1180bp to À235bp, including TB1-TB4) promoter (named pGL3-AXL hereafter) and the pcDNA3.1-YAP1 plasmid was co-transfected into each cell line, and after 24 h we measured the luciferase activities. The luciferase activities of the AXL promoter were significantly enhanced in HEK293-T cells when co-transfected with the YAP1 gene, but not with the vector control (Po0.001, see Supplementary Figure 2b ). As for PLC/PRF/5 cells expressing high endogenous YAP protein, transfection with the pGL3-AXL vector alone significantly upregulated reporter activity (Po0.001); cotransfection with the pcDNA3.1-YAP1 vector further enhanced the luciferase signal (Po0.01, Figure 4c ). When YAP1 expression was downregulated by siYAP1a or siYAP1b transfection in PLC/PRF/5 cells, the AXL promoter reporter activity was prominently decreased compared with that in control siRNA-transfected cells (both Po0.001, Figure 4c ). In addition, knockdown of YAP1 expression also downregulated the AXL level (both protein and mRNA) in four other HCC cell lines, H2P, Hep3B, MHCC-97L and MHCC97-H, which revealed high endogenous AXL levels ( Figure 4d ). the stable transfectants with concomitant increase in the YAP expression level. When measuring the phosphorylated form of AXL by enzyme-linked immunosorbent assay (Figure 5d ), there was significant upregulation of p-AXL in both MIHA-YAP1 clones when grown in the presence of serum or serum-starved conditions. We also measured the growth arrest-specific 6 ligand for AXL receptor by quantitative PCR (Figure 5e ). Interestingly, the growth arrest-specific 6 mRNA levels were markedly downregulated in MIHA-YAP1 cells when compared with that of the MIHA-Vec control, implicating a possible negative autocrine feedback loop. Transient knockdown of YAP1 expression by siRNA in PLC/PRF/5 cells reduced both protein (Figure 5b ) and transcriptional levels (see Supplementary Figure 3b ) of AXL. As MAP and Akt kinases are well-documented AXL downstream signaling pathways, we measured ERK1/2 and Akt activities and found that the YAP/ AXL expression level apparently affected the phosphorylation of ERK1/2 and Akt (S-473) ( Figure 5a ). As YAP does not possess the kinase domain to directly activate ERK1/2 or AKT, we suggest that this effect can be attributed to AXL kinase, and the finding implies that YAP is linked to tumor maintenance and HCC-related oncogenic signaling pathways. Meanwhile, downregulation of YAP1 in PLC/PRF/5 cells reduced the phosphorylation of ERK1/2, with a concomitant reduction in AXL level (Figure 5b) . Furthermore, as shown in the MIHA-YAP1b clone, siRNA-mediated knockdown of AXL expression reduced the phosphorylation of ERK1/ 2, but not the YAP expression level (Figure 5c ). However, the p-AKT level was apparently unaffected or revealed undetectable change, suggesting that Akt may be activated by pathway(s) other than AXL.
AXL mediates YAP1-induced cell proliferation and migration in HCC To investigate whether AXL kinase mediates the oncogenic functions of YAP1 in HCC, we transiently knocked down expression of AXL in the MIHA-YAP1b stable transfectant (which expressed the higher level of YAP protein), and assayed the tumorigenic and metastatic potentials as shown above. Compared with the vector control (MIHA-YAP1b-shCon), both the shAXL1 and shAXL2 transfectants revealed lower cell viability and proliferation, in particular when grown in serum-free media (Figure 6a ). Similar knockdown effects were observed in invasion (Figure 6b ) and wound healing (Figure 6c ) abilities in MIHA-YAP1b-shAXL cells. Finally, to further confirm the role of AXL in mediating YAP signaling in HCC, we conducted a 'rescue' experiment of the cell proliferation and wound healing phenotypes when AXL is put back into the PLC/PRF/5 system, in which YAP1 was knocked down (Figure 7a ). AXL could rescue partly, if not all, the cell migration and proliferation activities as demonstrated in the wound healing ( Figure 7b ) and MTT (Figure 7c ) assays, respectively. This may imply that YAP activates multiple pathways, and AXL receptor kinase is one of the key mediators of YAP-dependent liver oncogenesis.
Discussion
Tumors are complex biological systems resulting from a progressive sequence of genetic alterations that drive malignant transformation of normal cells and neoplasm invasiveness. The advent of integrative cross-species oncogenomics approaches has begun to uncover the genetic alterations in cancer genome coding for tumorigenesis and metastasis (Peeper and Berns, 2006; Zender and Lowe, 2008) . Our recent study in a mosaic HCC mouse model has identified a focal lesion at the 9qA1 locus (syntenic to human 11q22), in which YAP1 is defined as a bona fide oncogenic driver in hepatic carcinogenesis (Zender et al., 2006) . In this study, we investigated the molecular mechanisms of YAP1-induced tumorigenesis in a non-neoplastic hepatocyte cell line, MIHA, and elucidated a novel molecular link between the Hippo signaling and MAP pathways through the activation of AXL receptor kinase in HCC.
YAP1 is a potent transcriptional co-activator controlling organ size and apoptosis. At present, there is strong evidence showing that dysregulation of Hippo signaling and YAP1 expression could cause tumorigenesis and loss of organ size control. Using a conditional transgenic mouse model, YAP was found to be upregulated in the liver and there was enhanced transcription of certain target genes, such as Ki67, c-myc, SOX4, H19 and AFP, mainly affecting hepatocyte proliferation (Dong et al., 2007) . The data presented in this study provide strong evidence for the oncogenic properties of YAP1 in transforming the nontumorigenic hepatocyte cell line MIHA into tumorigenic phenotypes that exhibit anchorage-independent growth, inhibition of apoptosis, cellular proliferation, motility and invasion in vitro, and that transduce tumor formation in subcutaneous xenograft nude mouse models. However, the exact downstream mechanisms causing the tumorigenic properties of YAP remain elusive.
The phenotypic changes driven by YAP1 may involve dedifferentiation of hepatic MIHA cells into a more embryonic stage, followed by transformation into HCClike cells. We have observed downregulation of YAP1 transcription during cellular differentiation (unpublished data), supporting a recent study that YAP has the capability to induce dedifferentiation and expansion of multipotent progenitor cells in the small intestine (Camargo et al., 2007) . Collectively, the oncogenic effects of the YAP1 oncogene in hepatocytes are similar to the outgrowth phenotypes of the Drosophila ortholog Yki, which increases cell proliferation and decreases cell death (Huang et al., 2005; Dong et al., 2007) . Whether YAP1 also has a role in the cancer 'stemness' properties of HCC remains to be further elaborated in future investigations.
We identified AXL as one of the most upregulated genes in the YAP-transformed MIHA cell line; AXL is a unique transmembrane receptor tyrosine kinase consisting of juxtaposed immunoglobulin-like domains and fibronectin type III repeats in the extracellular region (Hafizi and Dahlback, 2006) . Overexpression of AXL has been implicated in several malignancies, including colon (Craven et al., 1995) , prostate (Sainaghi et al., 2005) , breast (Berclaz et al., 2001) , stomach (Sawabu et al., 2007) and HCC (Tsou et al., 1998 ). Furthermore, a high level of AXL activity is associated with metastatic lesions in melanoma (Bittner et al., 2000) , as well as with poor clinical outcomes in lung adenocarcinoma (Shieh et al., 2005) . AXL is characterized as an oncogenic kinase by its promotion of cancer cell survival, proliferation, invasion and migration. The most wellknown aspect of AXL in cancer is that it protects against apoptosis due to serum starvation (Goruppi et al., 1996) ( Demarchi et al., 2001) , phosphoinositide 3-kinase/Akt (Hasanbasic et al., 2004) and ERK 1/2 kinases (Sainaghi et al., 2005) . AXL is also involved in angiogenesis and in the neovascularization process, as well as in regulating matrix metallopeptidase-9 activity (Tai et al., 2008) . As a matter of fact, all these oncogenic features were observed in the YAP1-transformed MIHA tumors both in vitro and in vivo: (1) increased cell survival and growth in serum-free conditions, (2) enhanced aptitudes for cell anchorage-independent growth, migration and invasion, (3) phosphorylation of MAP kinases and (4) high microvascular density and Ki67 proliferative index in xenograft tumor explants. In addition, a marked induction of HCC biomarker AFP was detected in the culture supernatant of MIHA-YAP1 clones by clinical biochemical assay, as well as in the MIHA-YAP1-transformed liver tumors. Notwithstanding the fact that AXL receptor kinase is a convincing downstream target of YAP, we further demonstrated the binding of YAP protein to the TEAD-containing AXL promoter by luciferase reporter and ChIP assays. It is well established that YAP regulates cell growth through TEAD transcription factors in both cancer and progenitor cells (Cao et al., 2008; Zhao et al., 2008b) , and that these transcription factors are usually required for YAP-induced cell growth, malignant transformation and epithelialto-mesenchymal transition. Our data also reveal the critical role of AXL in YAP1-mediated oncogenic functions, as knockdown of AXL expression impaired the migration and invasion of YAP1-transformed MIHA cells, as well as their viability under serum starvation conditions, whereas rescuing AXL in YAP1-knockdown PLC/PRF/5 HCC restored the cell proliferation and migration phenotypes to a certain extent. Targeting AXL with monoclonal antibody or kinase inhibitor suppressed cancer cell invasiveness and chemoresistance in non-small-cell lung cancer (Lay et al., 2007) and breast cancer . In our studies, knockdown of either YAP or AXL expression decreased the tumorigenic and metastatic potentials of the HCC cell line. Further investigations of YAP as a druggable target in animal models and clinical studies of the potential of AXL inhibitor (for example, sulfasalazine) for the treatment of advanced HCC are underway.
In conclusion, this paper defines certain mechanistic properties of the YAP oncogene in HCC development, identifies a novel molecular link between Hippo signaling and the MAP kinase pathway through YAP/TEADmediated activation of AXL and potentially implicates new molecular targeted therapies for treating this aggressive malignancy.
Materials and methods
Cell lines and antibodies
The human HCC cell lines PLC/PRF/5 and Hep3B, and human embryonic kidney cell line HEK293-T were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). The immortalized non-tumorigenic human hepatocyte cell line MIHA and human HCC cell lines H2P, MHCC97L and MHCC97H were used as described previously (Liu et al., 2009) . All cell lines were cultured according to standard procedures (Wong et al., 2003) . The following antibodies were used: rabbit polyclonal antibodies directed against human YAP (H-125; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), human AXL (Cell Signaling Technology Inc., Danvers, MA, USA) and human Alpha-1-Fetoprotein (AFP, Dako A/S, Glostrup, Denmark); rabbit monoclonal antibodies against human p44/42 MAP kinase and human phospho-p44/42 MAP kinase (Thr202/Tyr204) (Cell Signaling Technology Inc.); and mouse monoclonal antibodies against human Ki67 (BD Biosciences, San Jose, CA, USA) and human b-actin (Sigma Co., St Louis, MO, USA).
Ectopic expression of YAP1 in MIHA cell line The MIHA cell line was transfected with full-length YAP1 complementary DNA (NM_006106.3) plasmid (pcDNA3.1-YAP1) or pcDNA3.1 empty vector (control) using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA), and grown in complete medium containing 300 mg/ml G418 (Sigma). Two separate neomycin-resistant clones (MIHAYAP1a, MIHA-YAP1b) with high expression levels of YAP were selected for further studies. Culture supernatants from each stable transfectant (2 Â 10 5 cells cultured for 5 days) were harvested for measurement of AFP levels using the AFP ACS-180 immunoassay (Bayer Group, Leverkusen, Germany).
Transient knockdown of YAP1 and AXL in HCC cells
Small-interfering RNA oligonucleotides targeting the human YAP1 gene (siYAP1a: 5 0 -GGAAUUGAACAAUGCGtt-3 0 ; siYAP1b: 5 0 -GCUUUGAGUUCUGACAUCCtt-3 0 ) and non-targeting siRNA (Silencer Negative control #1siRNA, siCon) (Ambion Inc., Austin, TX, USA) were transfected at 100 pmol into semiconfluent PLC/PRF/5 cells and labeled as PLC-siYAP1a, PLC-siYAP1b and PLC-siCon, respectively. YAP1 Stealth RNAi siRNA (Cataolog #HSS115942 and #HSS115944; sequences available at Invitrogen) was also used to generate siYAP1c and siYAP1d transfectants.
Retroviral-based short hairpin RNA constructs targeting AXL (shAXL1: 5 0 -AGATCCCCACATGGAGACCTACACA GCTTCAAGAGAGCTGTGTAGGTCTCCATGTTTTTTG GAACTGAG-3 0 ; shAXL2: 5 0 -AGATCCCCGAAAGAAGGAG ACCCGTTATTCAAGAGATAACGGGTCTCCTTCTTTCTT TTTGGAACTCGAG-3 0 and the empty pSUPER.retro.puro vector as control (shCon) were obtained from Oligoengine (Seattle, WA, USA). The MIHA-YAP1 clones, grown to 80% confluence, were transfected with purified shAXL reagents or vector control. After overnight incubation, the transfected cells were tested for changes in tumorigenic phenotypes as described in Supplementary Methods. Protein lysates and/or total RNA were extracted from cell cultures on day 3 post transfection. In addition, Dharmacon (Lafayette, CO, USA) ON-TARGETplus SMARTpool siRNAs targeting human AXL (catalog # L-003104-00-0020, sequence available at Thermo Scientific (Rockford, IL, USA)) or control siRNA (Dharmacon, catalog #D-001810-10-50) were also used for AXL-knockdown experiments in MIHA-YAP1 and PLC/ PRF/5 cells.
AXL rescue experiment in YAP1-knockdown PLC/PRF/5 cells Human AXL complementary DNA (NM_021913.2) obtained from OriGene Technologies (Catalog #sc112559; Rockville, MD, USA) was subcloned (at EcoR1 and Not1 sites) into the pCI-neo mammalian expression vector (Promega, Madison, MI, USA). PLC/PRF/5 cells grown to near confluence were co-transfected with (i) 50 pmol of YAP1 Stealth siRNA (HSS115944) or silencer negative control #1siRNA (siCon) and (ii) 1 mg of pCl-AXL plasmid or pCI-neo vector control. At days 3 and 5 post transfection, cells were harvested for biochemical analysis of YAP and AXL expression levels, using quantitative PCR and immunoblotting as described herein. After optimizing the conditions, MTT and wound healing assays (see Supplementary Methods) were also conducted on PLC-siYAP1c and PLC-siYAP1d after rescued transfection by pCI-AXL.
Tumor xenograft mouse model
Male BALB/c athymic mice (nu/nu, 4-6 weeks of age) were housed under specific pathogen-free conditions at the Animal Laboratory in the Department of Surgery, The University of Hong Kong (Pokfulam, Hong Kong). The Committee on the Use of Live Animals in Teaching and Research approved the protocols used for animal handling in this study. For the xenograft tumor growth assay, MIHA-Vec, MIHA-YAP1a and MIHA-YAP1b cells (2 Â 10 6 cells) were injected subcutaneously into the left flank of the mice (n ¼ 5 mice per group) and signs of tumor formation were observed daily. Tumor volume (V) was measured weekly as V ¼ length Â width 2 /2, according to published procedures (Bueno et al., 2008) . Mice were killed at 8 weeks and the tumors were excised for histopathological examination and immunohistochemistry analyses.
Quantitative PCR, immunohistochemistry and western blot
The quantitative PCR primers used were as follows: AXL-QF: 5 0 -CGTAACCTCCACCTGGTCTC-3 0 , AXL-QR: 5 0 -TCCCA TCGTCTGACAGCA-3 0 , GAPDH-QF: 5 0 -AGCCACATCGC TCAGACAC-3 0 , GAPDH-QR: 5 0 -GCCCAATACGACCAA ATCC-3 0 , growth arrest-specific 6-QF: 5 0 -ATGGCATGTGG CAGAC AAT-3 0 , growth arrest-specific 6-QR: 5 0 -CCCTG TTGACCTTGATGACC-3 0 . Experiments were conducted in duplicate in three independent assays. Relative transcriptional folds were calculated as 2
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. Procedures for immunostaining and western blot were performed routinely, as reported previously (Wong et al., 2003; Luk et al., 2005) ; details are given in the Supplementary Methods.
Luciferase assay
The AXL promoter reporter plasmid pGL3-AXL was generated by PCR amplification of PLC/PRF/5 cell genomic DNA, which was extracted using a mammalian genomic DNA miniprep kit (Sigma), and then subcloned into the luciferase reporter vector pGL3-basic (Promega). The promoter region of AXL extends from À1180 bp to À235 bp of the transcriptional start site of the human AXL gene (NCBI Gene ID 558). We used the following primers for cloning the promoter region: AXLF: 5 0 -CCGCTCGAGCCTCCTCCTCACAGA CATCC-3 0 ; and AXLR: 5 0 -CCCAAGCTTCTGTCCCTCTG GGCTCTG-3 0 . Semiconfluent HEK293-T or PLC/PRF/5 cells in 24-well plates were transfected in triplicate with pcDNA3.1-YAP, pcDNA3.1 vector, siYAP1a, siYAP1b, siCon, pGL3-basic and AXL promoter luciferase reporter construct (pGL3-AXL). Renilla luciferase vector phRL-tk (Promega) was co-transfected as an internal control. Luciferase activity was determined 24 h after transfection using a Dual-Glo luciferase assay system (Promega). All experiments were performed in triplicate and repeated three times.
ChIP assay
The ChIP assay was conducted using the Magna ChIP A Chromatin Immunoprecipitation Kit according to the manual (Millipore, Billerica, MA, USA). Briefly, 1 Â 10 7 MIHA or MIHA-YAP1 cells were fixed with 1% formaldehyde (Sigma) and nuclear extracts were isolated. The sonicated nuclear lysates were immunoprecipitated with 1 mg anti-YAP antibody (H-125, Santa Cruz) or rabbit IgG. After purification of the immunoprecipitated DNA, a 200-bp region of the AXL promoter encompassing the putative TB that were predicted by Matinspector (Genomatix Software GmbH, Mu¨nchen, Germany) was amplified by PCR using the following primers: AXL-1F: 5 0 -CAGCCTCC TCCTCACAGACA-3 0 , AXL-1R: 5 0 -GAGCCCTGATCATTCCACTG-3 0 , AXL-2F: 5 0 -C CTTG TCCGAGGAGCCGAGA-3 0 , AXL-2R: 5 0 -CTGAGCCAGT GAGGCCGTGT-3 0 . The ChiP assay was similarly conducted in PLC/PRF/5 cells after transient knockdown of YAP expression.
Statistical analysis
The SPSS statistical package (SPSS, Chicago, IL, USA) was used for data analysis. The cumulative tumor growth from week 4 to week 8 was calculated by measuring the AUC of the tumor growth curve for each mouse, using the trapezoidal method. Independent Student's t-test was used to assess the effects of YAP or shAXL in the cell lines and in the cumulative tumor growth. P-value o0.05 was considered significant.
